The public conversation about stem cell therapy has expanded well beyond its orthopedic origins. Patients researching regenerative medicine now encounter claims ranging from the well-evidenced, such as stem cells for knee arthritis where multiple randomized controlled trials exist, to the highly speculative, where clinics offer cell-based treatment for complex systemic diseases with limited or no clinical evidence to support the specific application.
The challenge for a patient trying to make sense of this landscape is enormous. The underlying science of stem cell biology is genuinely promising. Mesenchymal stem cells (MSCs) have demonstrated real immunomodulatory and tissue-supportive properties across numerous laboratory and clinical investigations. The question is not whether stem cell biology is scientifically meaningful. It is whether specific clinical applications for specific conditions in specific patient populations have sufficient evidence to support informed decision-making.
This article attempts to provide that honest map: where the evidence is stronger, where it remains preliminary, what responsible clinical practice looks like in this space, and how patients should evaluate the claims they encounter.
Beyond Orthopedics: Expanding Applications in Regenerative Medicine
Why Systemic Applications Are More Complex
Musculoskeletal applications of stem cell therapy have several biological advantages that systemic applications do not share. When a physician injects autologous stem cells into a knee joint under ultrasound guidance, the biological material goes directly to the anatomical target. The cells do not need to navigate the vascular system to find the joint. The target tissue is accessible, visible under imaging, and physically reachable with a needle. The distance between delivery and target is measured in centimeters.
Systemic applications require a fundamentally different delivery strategy. To treat a diseased liver, inflamed bowel, damaged cardiac tissue, or a condition affecting the central nervous system, cells must either be delivered directly into the target organ through a more invasive procedure or be administered intravenously and rely on homing mechanisms to reach the intended destination. Homing refers to the capacity of stem cells to migrate from the bloodstream toward sites of inflammation or injury, guided by chemical signals released by damaged tissue.
These homing mechanisms exist and have been studied extensively, but they are less precise and predictable than direct anatomical injection. The proportion of intravenously administered MSCs that actually reach and persist at the target organ is substantially lower than the proportion that reach a directly injected site. This reduced delivery efficiency means that systemic applications require larger cell doses, more sophisticated delivery strategies, or both.
Additional layers of complexity include the blood-brain barrier, which prevents most cells and large molecules in the bloodstream from entering the central nervous system under normal conditions, making neurological applications particularly challenging from a delivery standpoint. Organ-specific immune environments, the complexity of chronic disease pathophysiology, and the long natural history of most systemic conditions all create challenges that do not exist in the same form for a peripheral joint injection.
These are not reasons to dismiss systemic applications. They are reasons why the evidence base for systemic stem cell therapy is less mature than for musculoskeletal applications, and why patients considering these treatments deserve a clear account of what is known and what is not.
What the Research Frontier Looks Like
The global clinical trial landscape for stem cell therapies in systemic conditions is active and growing. A 2024 comprehensive analysis examining over 1,100 stem cell clinical trials across therapeutic areas found that MSC-based approaches account for the majority of trials, with autoimmune and inflammatory conditions representing a large and growing category of active investigation.
Understanding clinical trial phases is essential context for patients evaluating research citations. Phase 1 trials primarily examine safety and establish appropriate dosing in a small number of patients, typically fewer than 30. They are not designed to demonstrate efficacy. Phase 2 trials examine preliminary efficacy in a slightly larger population, typically 50 to 200 patients, and begin to define which patient subgroups may respond. Phase 3 trials are large randomized controlled trials designed to provide definitive evidence of efficacy and safety in the populations that will ultimately receive treatment if the therapy is approved. Most stem cell trials for systemic conditions currently sit at Phase 1 or Phase 2.
The fact that a therapy is in clinical trial does not mean it is established. Phase 3 completion and regulatory review separate investigational from approved. In December 2024, the FDA granted the first approval of a commercial MSC product, Ryoncil (remestemcel-L), specifically for steroid-resistant acute graft-versus-host disease in pediatric patients. This landmark approval demonstrates that MSC therapies can achieve regulatory standards, but it applies to a narrow specific indication, not to systemic applications broadly.
Conditions Being Explored
Autoimmune and Inflammatory Systemic Conditions
Autoimmune conditions represent one of the most scientifically rational applications for MSC therapy because of the well-characterized immunomodulatory properties of mesenchymal stem cells. MSCs do not attack the immune system. Rather, they modulate it, creating a shift toward tolerance and away from the exaggerated self-directed immune responses that characterize autoimmune disease.
The specific mechanisms include induction of T-regulatory cells, which function as suppressors of excessive immune activation; secretion of indoleamine 2,3-dioxygenase (IDO), an enzyme that creates a local immunosuppressive environment; production of prostaglandin E2 (PGE2), which modulates macrophage polarization toward anti-inflammatory phenotypes; and inhibition of natural killer cell activity.
Conditions being actively studied include:
Rheumatoid arthritis, in which MSC therapy is hypothesized to reduce synovial inflammation and potentially protect joint cartilage through the same immunomodulatory mechanisms. A 2025 meta-analysis of randomized controlled trials found that MSC transplantation may improve outcomes in RA, though the evidence base remains limited compared to established disease-modifying antirheumatic drugs. Established RA care with rheumatologist-directed DMARD therapy remains the standard of care; investigational MSC approaches are not a replacement for it. MSC therapy in RA, where offered, is best understood as a complement to or potential future adjunct to established rheumatologic management, not a substitute for it.
Systemic lupus erythematosus (SLE), where multiple clinical trials, primarily from Chinese research groups using umbilical cord-derived MSCs, have reported meaningful reductions in disease activity scores. A 2025 meta-analysis reported a 92.5 percent survival rate in treated SLE patients and statistically significant improvements in SLEDAI disease activity scores. These results are promising but must be interpreted in the context of study quality, population characteristics, and the lack of large Western-context Phase 3 data.
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Crohn’s disease has the most clinical trial activity of any systemic condition in the MSC space. A randomized controlled trial of adipose-derived MSCs for perianal Crohn’s fistulas resulted in FDA approval of a specific cell product (Alofisel) in Europe. Systemic MSC therapy for luminal Crohn’s disease shows a 56 percent remission rate in one major trial versus 38 percent with placebo. This represents meaningful signal, though larger trials are needed to establish this definitively.
Multiple sclerosis, where MSC therapy has been studied for both relapsing-remitting and progressive forms. Results have been more modest than in SLE and IBD, and the 2025 meta-analysis noted that MSC transplantation may not significantly improve outcomes in MS based on current evidence. Research continues, with better understanding needed of which MS patient subgroups may respond.
Organ Support and Functional Decline
Research into stem cell applications for organ-level disease reflects the broad tissue support capabilities that MSCs have demonstrated in preclinical models.
Liver fibrosis and cirrhosis research explores whether MSCs delivered either intravenously or through direct portal vein infusion can reduce fibrosis and support hepatocyte function. Preclinical data is encouraging; MSCs appear to reduce collagen deposition and support liver regeneration in animal models. Clinical data in human liver disease is early, with small studies showing safety and possible efficacy signals in Child-Pugh A and B cirrhosis patients. Larger randomized trials are needed before this application can be considered established.
Kidney disease research examines whether MSC therapy can protect renal tubular cells, reduce fibrosis, and support function in patients with chronic kidney disease. Preclinical evidence is substantial; clinical evidence in humans remains early-stage.
Cardiac applications have a longer history than most organ-based stem cell programs. Following a major myocardial infarction, the heart loses contractile tissue that does not regenerate spontaneously. Cardiac stem cell therapy research, which began in earnest in the early 2000s, has had a turbulent history with some high-profile cases of data integrity concerns in foundational studies. The current status of cardiac MSC therapy is that research continues with more rigorously designed trials, but definitive evidence of meaningful functional cardiac recovery has not yet been established in large Phase 3 trials.
Pulmonary applications received significant attention during and after the COVID-19 pandemic, as MSC-based approaches were evaluated for ARDS and post-COVID pulmonary inflammation. Multiple small trials were conducted rapidly; results have been mixed and the evidence base is not yet sufficient to establish these approaches as standard care.
Metabolic Conditions
Type 2 diabetes represents an area of active exploration because MSCs appear to have effects on insulin sensitivity, adipose tissue inflammation, and in some studies, pancreatic beta cell support. Small clinical trials have shown improvements in glycemic markers in type 2 diabetic patients following MSC infusion. The mechanisms are plausible, involving reduction of adipose inflammation and improvement of insulin receptor signaling. However, established pharmacological and lifestyle management of type 2 diabetes remains far better evidenced than any current stem cell approach, and MSC therapy for diabetes outside of clinical trials would represent a departure from the standard of care that requires careful patient-physician discussion.
What Patients Should Understand About This Category
Where Evidence Is Preliminary vs. Established
The honest answer is that most systemic applications of stem cell therapy remain investigational. This is not a dismissal of the science. It is an acknowledgment of where the evidence currently sits and what that means for clinical decision-making.
The strongest evidence base for MSC therapy in systemic conditions is in:
- Steroid-resistant acute GVHD in children (FDA-approved indication)
- Perianal Crohn’s fistulas with a specific approved product (Alofisel, approved in Europe)
- Preliminary positive signals in SLE and IBD from multiple trials
Applications with active research but requiring more evidence:
- Rheumatoid arthritis, liver fibrosis, kidney disease, cardiac injury, metabolic syndrome, multiple sclerosis
Applications where the evidence is very early or largely preclinical:
- Most neurological conditions beyond the specific MS research programs, most organ failure states, most metabolic conditions beyond diabetes pilot studies
The distinction between orthopedic musculoskeletal applications, which have multiple randomized controlled trials for specific indications like knee OA, and most systemic applications, where evidence is thinner and more preliminary, is real and clinically significant. Patients should not assume that because stem cell therapy has meaningful evidence for joint pain, the same quality of evidence supports a specific systemic application they are considering.
What Responsible Clinics Say About Systemic Applications
A responsible regenerative medicine clinic offering any systemic stem cell application will:
Distinguish clearly between applications with established evidence and those that are investigational. They will tell a patient explicitly that a given application is being explored through early-phase trials rather than claiming established efficacy.
Provide published research for the patient to review. Claims about efficacy should be traceable to peer-reviewed publications that the patient can read and discuss with their primary physician or specialist.
Not substitute stem cell therapy for established care. A patient with rheumatoid arthritis should be under rheumatological management with appropriate disease-modifying drugs. A patient with active inflammatory bowel disease should be under gastroenterological care. Stem cell therapy offered outside of this established care context raises serious clinical concerns.
Have explicit protocols that are based on published research or IRB-approved investigation. When a clinic offers an investigational application, they should be able to describe the clinical rationale, the delivery protocol, and the monitoring plan in detail.
How to Evaluate Claims in This Area
The question patients most need to ask is not “does this work?” but rather “what is the quality and volume of evidence that this specific treatment for my specific condition produces the outcomes being claimed?”
Relevant questions to ask any clinic offering systemic stem cell applications:
What phase are the clinical trials that study this treatment for my condition? Phase 1 safety data does not demonstrate efficacy. Phase 3 randomized data is the gold standard.
What specific peer-reviewed publications support this application? Ask for the citations and review them, or share them with a physician you trust for interpretation.
Is this procedure being offered as part of an IRB-approved protocol or patient registry? Participating in a monitored registry with appropriate informed consent is a meaningful indicator of clinical seriousness in an investigational context.
What are the specific risks of this procedure as applied to my condition? Every intervention has risks; a clinician who cannot articulate the specific risks of their proposed intervention is not providing adequate informed consent.
What is the cost and is it refundable if the treatment does not produce any benefit? Financial transparency matters in investigational medicine.
Red flags that should prompt caution include clinics that claim established efficacy for conditions where Phase 3 evidence does not exist, clinics that dismiss the relevance of clinical trial evidence and rely primarily on testimonials, clinics that offer to treat any systemic condition without expressed criteria for patient selection, and clinics that discourage patients from consulting their existing specialists about the proposed treatment.
The scientific promise of MSC therapy for systemic conditions is real. The clinical evidence to fulfill that promise is still being generated. Patients deserve both the honest account of what is known and the acknowledgment that what is being explored today may become established care tomorrow. A responsible clinic communicates this accurately without either dismissing the potential or overstating the certainty.
Sources
- FDA Approval of Ryoncil (Remestemcel-L) for Steroid-Refractory Acute Graft-Versus-Host Disease in Pediatric Patients (FDA)
- Efficacy and Safety of Mesenchymal Stromal Cell Transplantation in Autoimmune and Rheumatic Immune Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (PubMed, 2025)
- Clinical Trial Landscape for Stem Cells in Autoimmune and Inflammatory Diseases: A Comprehensive Analysis (PMC)
- Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus (PubMed)
- Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases (PMC, 2025)
- Ryoncil (Remestemcel-L): The First Approved Cellular Therapy for Steroid-Refractory Acute GVHD (PMC)
Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.